Evonik has partnered with Stanford University to develop a mRNA drug transport technology which aims to deliver mRNA to different tissues and organs in the human body.
If successful, Evonik will expand its product range based on mRNA transport technology.
(Source: Evonik)
Essen/Germany – Specialty chemicals group Evonik is cooperating with the U.S. university Stanford in its search for new ways to transport mRNA-based drugs to the right places in the body. The goal of the three-year collaboration is to develop a technology that goes beyond the current possibilities of lipid nanoparticles, Evonik recently announced in Essen, Germany.
To this end, a polymer-based system will be developed, which the company will license and market. The aim is to expand the potential applications of mRNA therapeutics to better combat diseases such as cancer and Aids in the future.
If successful, Evonik would thus expand its product range based on mRNA transport technology and drive forward the portfolio restructuring of the Nutrition & Care division toward system solutions. The share of such system solutions in the division is expected to rise from 20 percent today to more than 50 percent by 2030.
Evonik already produces lipid nanoparticles (LNP) for the Corona vaccine from Biontech and Pfizer. Currently, Evonik's accessible market potential for LNP-based delivery systems is estimated to exceed 5 billion dollars by 2026, it added. However, competition in this area is also increasing.
Stand vom 23.03.2021
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planckstr. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://support.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.